CitroTech Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CitroTech Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.38M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $808.4K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $520.6K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $62.7K | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 31, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $387.1K | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $60.8K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $20.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 12, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.84M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($6.88M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($10.10M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.91M) | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | ($95.0K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($109.4K) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Sep 29, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.50M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($5.30M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($10.10M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.92M) | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | ($37.9K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($109.4K) | Apr 12, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $198.5K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $14.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.87M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.94M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($1.21M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($708.5K) | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | ($24.2K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Sep 29, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $194.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $4.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.4K | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 31, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.18M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $5.48M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $5.30M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.41M | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | $330.2K | Mar 31, 2023 |
| FY2022 | Oct 19, 2021 | $81 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Sep 29, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.92M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.16M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.06M | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | $383.1K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $9.4K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Sep 29, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.26M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.32M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $3.64M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $3.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($52.9K) | Jul 30, 2024 |
| FY2022 | Dec 31, 2020 | ($9.4K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $0 | Apr 12, 2022 |
| FY2020 | Dec 31, 2018 | $0 | Sep 29, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | May 10, 2021 | $53.0K | Mar 31, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($113.20M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($76.37M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($69.48M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($59.38M) | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | ($56.47M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($56.38M) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($56.27M) | Sep 29, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.27M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $775.1K | Mar 30, 2026 |
| FY2021 | Dec 31, 2021 | $5.5K | Apr 12, 2022 |
| FY2021 | Dec 31, 2020 | $0 | Apr 12, 2022 |
| FY2021 | Dec 31, 2019 | $0 | Apr 12, 2022 |
| FY2020 | Dec 31, 2018 | $0 | Sep 29, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2023 | Dec 31, 2023 | 0 | Jul 30, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 12, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18.52M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 6.14M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 97.55M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 93.95M | Jul 30, 2024 |
| FY2022 | Dec 31, 2021 | 22.95M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 22.95M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | 22.95M | Sep 29, 2021 |